BMP7 Gene Transfer via Gold Nanoparticles into Stroma Inhibits Corneal Fibrosis In Vivo

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Tandon, Ashish ^a,b   Sharma, Ajay ^a,b   Rodier, Jason T ^a,b   Klibanov, Alexander M ^c   Rieger, Frank G ^a   Mohan, Rajiv R ^a,b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD11B ANTIGEN; F ACTIN; FIBRONECTIN; GOLD NANOPARTICLE; OSTEOGENIC PROTEIN 1; POLYETHYLIMINE; POLYMER; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIFICATION; CONTROLLED STUDY; CORNEA CELL; CORNEA DISEASE; CORNEA OPACITY; DRUG ACTIVITY; FEMALE; GENE DELIVERY SYSTEM; GENE DOSAGE; GENE EXPRESSION; GENE LOCATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNITY; IN VIVO STUDY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OSTEOBLAST; PHOTOREFRACTIVE KERATECTOMY; RABBIT; SIGNAL TRANSDUCTION; SLIT LAMP; STEREOTACTIC PROCEDURE; STROMA CELL; WOUND HEALING;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; CELLS, CULTURED; CORNEA; CORNEAL DISEASES; CORNEAL STROMA; FEMALE; FIBROBLASTS; FIBROSIS; GENE DOSAGE; GENETIC THERAPY; GOLD; HUMANS; METAL NANOPARTICLES; RABBITS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFECTION; TREATMENT OUTCOME;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 84879127594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066434     Document Type: Article

References (55)

1. Mohan RR, Tovey JC, Sharma A, Tandon A, (2012) Gene therapy in the cornea: 2005-present. Prog Retin Eye Res 31: 43-64.
2. Nien CJ, Flynn KJ, Chang M, Brown D, Jester JV, (2011) Reducing peak corneal haze after photorefractive keratectomy in rabbits: prednisolone acetate 1.00% versus cyclosporine A 0.05%. J Cataract Refract Surg 37: 937-944.
3. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, et al. (2012) Steroids for Corneal Ulcers Trial Group. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol 130: 143-150.
4. Bedei A, Marabotti A, Giannecchini I, Ferretti C, Montagnani M, et al. (2006) Photorefractive keratectomy in high myopic defects with or without intraoperative mitomycin C: 1-year results. Eur J Ophthalmol 16: 229-234.
5. Camellin M, (2004) Laser epithelial keratomileusis with mitomycin C: indications and limits. J Refract Surg 20: S693-S698.
6. Thornton I, Xu M, Krueger RR, (2008) Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia. J Refract Surg 24: S68-S76.
7. Dougherty PJ, Hardten DR, Lindstrom RL, (1996) Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea 15: 537-540.
8. Jester JV, Nien CJ, Vasiliou V, Brown DJ, (2012) Quiescent keratocytes fail to repair MMC induced DNA damage leading to the long-term inhibition of myofibroblast differentiation and wound healing. Mol Vis 18: 1828-1839.
9. Rubinfeld RS, Pfister RR, Stein RM, Foster CS, Martin NF, et al. (1992) Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology 99: 1647-1654.
10. Safianik B, Ben-Zion I, Garzozi HJ, (2002) Serious corneoscleral complications after pterygium excision with mitomycin C. Br J Ophthalmol. 86: 357-358.
11. Wu KY, Hong SJ, Huang HT, Lin CP, Chen CW, (1999) Toxic effects of mitomycin-C on cultured corneal keratocytes and endothelial cells. J Ocul Pharmacol Ther 15: 401-411.
12. Campolongo MJ, Tan SJ, Xu J, Luo D, (2010) DNA nanomedicine: Engineering DNA as a polymer for therapeutic and diagnostic applications. Adv Drug Deliv Rev 62: 606-616.
13. Irache JM, Esparza I, Gamazo C, Agüeros M, Espuelas S, (2011) Nanomedicine: novel approaches in human and veterinary therapeutics. Vet Parasitol 180: 47-71.
14. Teli MK, Mutalik S, Rajanikant GK, (2010) Nanotechnology and nanomedicine: going small means aiming big. Curr Pharm Des 16: 1882-1892.
15. Wesselinova D, (2011) Current major cancer targets for nanoparticle systems. Curr Cancer Drug Targets 11: 164-183.
16. Cho YK, Uehara H, Young JR, Tyagi P, Kompella UB, et al. (2012) Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci 53: 2328-2336.
17. Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, et al. (2007) Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 48: 2030-2036.
18. Mohan RR, Sinha S, Katti KV, Kannan R, Stapleton WM, et al. (2007) Evaluation of polymeric- and gold-nanoparticles for gene delivery in the cornea. IOVS 48: ARVO E-Abstract 2733.
19. Vega E, Egea MA, Calpena AC, Espina M, García ML, (2012) Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery. Int J Nanomedicine 7: 1357-1371.
20. Sharma A, Tandon A, Tovey JC, Gupta R, Robertson JD, et al. (2011) Polyethylenimine-conjugated gold nanoparticles: Gene transfer potential and low toxicity in the cornea. Nanomedicine 7: 505-513.
21. Chen D, Zhao M, Mundy GR, (2004) Bone morphogenetic proteins. Growth Factors 4: 233-241.
22. Kim M, Choe S, (2011) BMPs and their clinical potentials. BMB Rep 44: 619-634.
23. Mohan RR, Kim WJ, Mohan RR, Chen L, Wilson SE, (1998) Bone morphogenic proteins 2 and 4 and their receptors in the adult human cornea. Invest Ophthalmol Vis Sci 39: 2626-2636.
24. You L, Kruse FE, Pohl J, Völcker HE, (1999) Bone morphogenetic proteins and growth and differentiation factors in the human cornea. Invest Ophthalmol Vis Sci 40: 296-311.
25. You L, Kruse FE, (2002) Differential effect of activin A and BMP-7 on myofibroblast differentiation and the role of the Smad signaling pathway. Invest Ophthalmol Vis Sci 43: 72-81.
26. Wall NA, Blessing M, Wright CV, Hogan BL, (1993) Biosynthesis and in vivo localization of the decapentaplegic-Vg-related protein, DVR-6 (bone morphogenetic protein-6). J Cell Biol 120: 493-502.
27. Wordinger RJ, Clark AF, (2007) Bone morphogenetic proteins and their receptors in the eye. Exp Biol Med (Maywood) 232: 979-992.
28. Dudley AT, Lyons KM, Robertson EJ, (1995) A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 9: 2795-2807.
29. Zouvelou V, Passa O, Segklia K, Tsalavos S, Valenzuela DM, et al. (2009) Generation and functional characterization of mice with a conditional BMP7 allele. Int J Dev Biol 53: 597-603.
30. Kinoshita K, Iimuro Y, Otogawa K, Saika S, Inagaki Y, et al. (2007) Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut 56: 706-714.
31. Zeisberg M, Kalluri R, (2008) Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 23: 1395-1398.
32. Saika S, Ikeda K, Yamanaka O, Flanders KC, Nakajima Y, et al. (2005) Therapeutic effects of adenoviral gene transfer of bone morphogenic protein-7 on a corneal alkali injury model in mice. Lab Invest 85: 474-486.
33. Jang JW, Lim H, Cho Y, Kwon OW, Kim DS (2009) BMP-7 induces wound healing without neovascularization and opacification in a corneal alkali injured mouse model. Invest Ophthalmol Vis Sci 50: E-Abstract 4549.
34. Sharma A, Mehan MM, Sinha S, Cowden JW, Mohan RR, (2009) Trichostatin A inhibits corneal haze in vitro and in vivo. Invest Ophthalmol Vis Sci 50: 2695-2701.
35. Mohan RR, Hutcheon AE, Choi R, Hong J, Lee J, et al. (2003) Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK and PRK. Exp Eye Res 76: 71-87.
36. Netto MV, Mohan RR, Sinha S, Sharma A, Gupta PC, et al. (2006) Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. J Refract Surg 22: 562-574.
37. Thomas M, Klibanov AM, (2003) Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci USA 100: 9138-9143.
38. Mohan RR, Sinha S, Tandon A, Gupta R, Tovey JC, et al. (2011) Efficacious and safe tissue-selective controlled gene therapy approaches for the cornea. PLoS One. 6: e18771.
39. Tandon A, Tovey JC, Waggoner MR, Sharma A, Cowden JW, et al. (2012) Vorinostat: a potent agent to prevent and treat laser-induced corneal haze. J Refract Surg 28: 285-290.
40. Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, et al. (1998) The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 142: 873-881.
41. Yeh LC, Tsai AD, Lee JC, (2002) Osteogenic protein-1 (OP-1, BMP-7) induces osteoblastic cell differentiation of the pluripotent mesenchymal cell line C2C12. J Cell Biochem. 87: 292-304.
42. Davies MR, Lund RJ, Hruska KA, (2003) BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol. 14: 1559-1567.
43. Buijs JT, Petersen M, van der Horst G, van der Pluijm G, (2010) Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis? Curr Pharm Des 16: 1291-1300.
44. Mitu G, Hirschberg R, (2008) Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Front Biosci 13: 4726-4739.
45. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, et al. (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13: 952-961.
46. Murray LA, Hackett TL, Warner SM, Shaheen F, Argentieri RL, et al. (2008) BMP-7 does not protect against bleomycin-induced lung or skin fibrosis. PLoS One 3: e4039.
47. Vesaluoma M, Teppo AM, Grönhagen-Riska C, Tervo T, (1997) Release of TGF-beta 1 and VEGF in tears following photorefractive keratectomy. Curr Eye Res. 16: 19-25.
48. Tandon A, Tovey JC, Sharma A, Gupta R, Mohan RR, (2010) Role of transforming growth factor Beta in corneal function, biology and pathology. Curr Mol Med 10: 565-578.
49. Jester JV, Petroll WM, Cavanagh HD, (1999) Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Prog Retin Eye Res 18: 311-56.
50. Mohan RR, Gupta R, Mehan MK, Cowden JW, Sinha S, (2010) Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp Eye Res 91: 238-245.
51. Mohan RR, Tovey JC, Gupta R, Sharma A, Tandon A, (2011) Decorin biology, expression, function and therapy in the cornea. Curr Mol Med 11: 110-128.
52. Hung FC, Zhao S, Chen Q, Overbeek PA, (2002) Retinal ablation and altered lens differentiation induced by ocular overexpression of BMP7. Vision Res 42: 427-438.
53. Piscione TD, Phan T, Rosenblum ND, (2001) BMP7 controls collecting tubule cell proliferation and apoptosis via Smad1-dependent and-independent pathways. Am J Physiol 280: F19-F33.
54. Wei Y, Hu Y, Lv R, Li D, (2006) Regulation of adipose-derived adult stem cells differentiating into chondrocytes with the use of rhBMP-2. Cytotherapy 8: 570-579.
55. Gould SE, Day M, Jones SS, Dorai H, (2002) BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 61: 51-60.